

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/532,320 Confirmation No. : 9143  
Applicants : Herman Jan Tijmen Coelingh Bennink et al.  
Filed : June 2, 2006  
Title : PHARMACEUTICAL COMPOSITIONS COMPRISING  
ESTETROL DERIVATIVES FOR USE IN CANCER  
THERAPY  
Group Art Unit : 1616  
Examiner : Kristie Latrice Brooks  
Customer No. : 28289

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the requirements of 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants hereby submit this Information Disclosure Statement ("IDS"). Pursuant to 37 C.F.R. § 1.98 (a), a legible copy of each reference cited in this IDS is provided herein. The cited United States patents and/or United States published patent applications are not enclosed pursuant to the waiver of this requirement under 37 C.F.R. § 1.98(a)(2)(i). For any reference not in the English language, all of the translations or partial translations within the possession, custody or control of, or readily available to individuals designed under 37 C.F.R. § 1.56(c) for the instant application have been enclosed pursuant to 37 C.F.R. § 1.98 (a)(3)(ii).

I hereby certify that this correspondence is being electronically submitted to the United States Patent and Trademark Office on January 11, 2010.

01/11/2010  
Date

  
Signature

Mary Ann Mulvihill

Typed Name of Person Signing Certificate

In this IDS, Applicants also disclose Office Actions from United States patent applications assigned to the assignee of this application that are directed to related technology. These office actions can be found in the following patent applications:

U.S. Pat. App. No.	Examiner
10/478,262	Hui
10/478,264	Hui
10/478,357	Hui
10/478,365	Chui
10/495,707	Sullivan
10/517,509	Jean-Louis
10/517,686	Chui
10/521,040	Chui


Additionally, Applicants wish to disclose that United State Patent Application No. 10/532,320 is a related patent application where no action has yet been issued by the United States Patent and Trademark Office.

Pursuant to 37 C.F.R. § 1.97(b)3, no fee is believed to be due for the submission of this Information Disclosure Statement, as it is being submitted before the mailing date of a first Office Action on the merits. Nevertheless, the Commissioner for Patents is hereby authorized to charge any fees which may be required to Deposit Account No. 23-0650. Please refund any overpayment to Deposit Account No. 23-0650.

The Applicants submit that they have complied with the requirements set forth in 37 C.F.R. §§1.56, 1.97 and 1.98, and therefore respectfully request that this Information Disclosure Statement and the cited references be considered and made of record.

Respectfully submitted,

THE WEBB LAW FIRM

By 

William H. Logsdon  
Registration No. 22,132  
Attorney for Applicants  
436 Seventh Avenue  
700 Koppers Building  
Pittsburgh, PA 15219  
Telephone: (412) 471-8815  
Facsimile: (412) 471-4094  
E-mail: webblaw@webblaw.com